Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium.

Archibald KM, Kulbe H, Kwong J, Chakravarty P, Temple J, Chaplin T, Flak MB, McNeish IA, Deen S, Brenton JD, Young BD, Balkwill F.

Oncogene. 2012 Nov 29;31(48):4987-95. doi: 10.1038/onc.2011.653.

2.

Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53.

Werness BA, Parvatiyar P, Ramus SJ, Whittemore AS, Garlinghouse-Jones K, Oakley-Girvan I, DiCioccio RA, Wiest J, Tsukada Y, Ponder BA, Piver MS.

J Natl Cancer Inst. 2000 Jul 5;92(13):1088-91.

3.

Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer.

Manderson EN, Presneau N, Provencher D, Mes-Masson AM, Tonin PN.

Mol Carcinog. 2002 Jun;34(2):78-90.

PMID:
12112314
4.

Acquisition of a second mutation of the Tp53 alleles immediately precedes epithelial morphological transformation in ovarian tumorigenicity.

Cai KQ, Wu H, Klein-Szanto AJ, Xu XX.

Gynecol Oncol. 2009 Jul;114(1):18-25. doi: 10.1016/j.ygyno.2009.03.023.

5.

Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.

Mehta SA, Christopherson KW, Bhat-Nakshatri P, Goulet RJ Jr, Broxmeyer HE, Kopelovich L, Nakshatri H.

Oncogene. 2007 May 17;26(23):3329-37.

PMID:
17130833
6.

Limited importance of the dominant-negative effect of TP53 missense mutations.

Stoczynska-Fidelus E, Szybka M, Piaskowski S, Bienkowski M, Hulas-Bigoszewska K, Banaszczyk M, Zawlik I, Jesionek-Kupnicka D, Kordek R, Liberski PP, Rieske P.

BMC Cancer. 2011 Jun 13;11:243. doi: 10.1186/1471-2407-11-243.

7.

Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells.

Yang G, Rosen DG, Mercado-Uribe I, Colacino JA, Mills GB, Bast RC Jr, Zhou C, Liu J.

Carcinogenesis. 2007 Jan;28(1):174-82.

8.

Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.

Svobodova K, Zemanova Z, Lhotska H, Novakova M, Podskalska L, Belickova M, Brezinova J, Sarova I, Izakova S, Lizcova L, Berkova A, Siskova M, Jonasova A, Cermak J, Michalova K.

Leuk Res. 2016 Mar;42:7-12. doi: 10.1016/j.leukres.2016.01.009.

PMID:
26851439
9.

CD164 regulates the tumorigenesis of ovarian surface epithelial cells through the SDF-1α/CXCR4 axis.

Huang AF, Chen MW, Huang SM, Kao CL, Lai HC, Chan JY.

Mol Cancer. 2013 Oct 5;12(1):115. doi: 10.1186/1476-4598-12-115.

10.

Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.

Parikh N, Hilsenbeck S, Creighton CJ, Dayaram T, Shuck R, Shinbrot E, Xi L, Gibbs RA, Wheeler DA, Donehower LA.

J Pathol. 2014 Apr;232(5):522-33. doi: 10.1002/path.4321.

11.

The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells.

Kulbe H, Hagemann T, Szlosarek PW, Balkwill FR, Wilson JL.

Cancer Res. 2005 Nov 15;65(22):10355-62.

12.

EGFR inhibition in glioblastoma cells induces G2/M arrest and is independent of p53.

Kapoor GS, Christie A, O'Rourke DM.

Cancer Biol Ther. 2007 Apr;6(4):571-9.

PMID:
17457042
13.

PAX8 expression in ovarian surface epithelial cells.

Adler E, Mhawech-Fauceglia P, Gayther SA, Lawrenson K.

Hum Pathol. 2015 Jul;46(7):948-56. doi: 10.1016/j.humpath.2015.03.017.

14.

Molecular characterization of an intact p53 pathway subtype in high-grade serous ovarian cancer.

Hayano T, Yokota Y, Hosomichi K, Nakaoka H, Yoshihara K, Adachi S, Kashima K, Tsuda H, Moriya T, Tanaka K, Enomoto T, Inoue I.

PLoS One. 2014 Dec 2;9(12):e114491. doi: 10.1371/journal.pone.0114491.

15.

Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer.

Kreuzinger C, Gamperl M, Wolf A, Heinze G, Geroldinger A, Lambrechts D, Boeckx B, Smeets D, Horvat R, Aust S, Hamilton G, Zeillinger R, Cacsire Castillo-Tong D.

Cancer Lett. 2015 Jul 1;362(2):218-28. doi: 10.1016/j.canlet.2015.03.040.

16.

[Effects of chemokine receptor and its ligand on migration of ovarian cancer cells].

Li F, Zhu HS, Han ZQ, Chen G, Gao QL, Jia P, Zhang AL, Xi L, Xu Q, Liao GN, Wang SX, Lu YP, Ma D.

Ai Zheng. 2005 Jan;24(1):23-7. Chinese.

PMID:
15642195
17.

Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma.

Jazaeri AA, Bryant JL, Park H, Li H, Dahiya N, Stoler MH, Ferriss JS, Dutta A.

Neoplasia. 2011 Oct;13(10):899-911.

18.

Requirement of wild-type p53 protein for maintenance of chromosomal integrity.

Honma M, Momose M, Tanabe H, Sakamoto H, Yu Y, Little JB, Sofuni T, Hayashi M.

Mol Carcinog. 2000 Aug;28(4):203-14.

PMID:
10972990
19.

Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival.

Mullany LK, Wong KK, Marciano DC, Katsonis P, King-Crane ER, Ren YA, Lichtarge O, Richards JS.

Neoplasia. 2015 Oct;17(10):789-803. doi: 10.1016/j.neo.2015.10.003.

20.

Mutation or loss of p53 differentially modifies TGFβ action in ovarian cancer.

Ó hAinmhire E, Quartuccio SM, Cheng W, Ahmed RA, King SM, Burdette JE.

PLoS One. 2014 Feb 20;9(2):e89553. doi: 10.1371/journal.pone.0089553.

Items per page

Supplemental Content

Support Center